Sun Pharma Advanced Research Co. Ltd. · NSE:SPARC

Sun Pharma Advanced Research — Investor Presentation (June 2010)

63 slides from Sun Pharma Advanced Research's investor presentation, June 2010

  1. Slide 1: Investor Presentation – June 2010

    Investor Presentation – June 2010

  2. Slide 2: Disclaimer

    Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “pl

  3. Slide 3: SPARC – Innovating, with measured risk

    SPARC – Innovating, with measured risk. A disciplined and systematic innovation process Focus on niche indications with predictable and sustainable market Develop products/technologies which solve unresolved problems and add meaningful value Early confirmation of the proof of concept Balanced resour

  4. Slide 4: Technology Platforms

    Technology Platforms Oral Injectables Topical • Gastro Retentive Innovative • Gastro Retentive Innovative • Dry Powder Inhalers ( DPI) Device (GRID) Device (GRID) • SMM Technology for • Wrap Matrix System • Wrap Matrix System Ophthalmic Formulations • GFR Technology for Once a Day Ophthalmic formula

  5. Slide 5: NDDS ORAL Products

    SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

  6. Slide 6: Challenges in CR products with “Absorption Window”

    Challenges in CR products with “Absorption Window” The Challenge Transit of dosage form from Controlled release of drugs the absorption area resulting into poor bioavailability Absorption from the small 4.5 m section of the upper GI tract Transit time: • Transporter mediated absorption 8 – 16 hrs •

  7. Slide 7: Gastro Retentive Innovative Device (GRID)

    Gastro Retentive Innovative Device (GRID) The Technology • Designed for retention in the stomach for longer time (~about 8 hours) • Combination of mechanisms • Flotation Inner coat – reactive • Size expansion gas generating coat IR coat • Mucoadhesion Key Advantages • Improves bioavailability of dru

  8. Slide 8: Baclofen GRS Capsules

    Baclofen GRS Capsules Extended release capsule formulation of baclofen with Proprietary Gastro Retentive Innovative Device(GRID) technology Once daily and recommended fed state dosing for optimal bioavailability and minimal sedation Baclofen GRS capsules will be available in 6 strengths i.e., 10 / 2

  9. Slide 9: Baclofen GRS - Established Clinical Efficacy

    Baclofen GRS - Established Clinical Efficacy Total of 388 healthy volunteers and 108 patients exposed to baclofen GRS capsules • 19 studies for comparative bioavailability and observation of food effect • 11 pilot studies to optimize final formulation of baclofen GRS capsules • 8 studies to determin

  10. Slide 10: Baclofen GRS Future Development Plan

    Baclofen GRS Future Development Plan US –505(b)(2) route. • IND approved by USFDA • Phase III, randomized, placebo controlled efficacy in 300 patients is initiated in USA • One open label safety study in 100 patients and a PK study in patient population is planned India • Baclofen GRS capsules are r

  11. Slide 11: Challenges in CR products with high solubility, high dose drugs

    Challenges in CR products with high solubility, high dose drugs High excipient to drug ratio Initial dose dumping – bigger dosage form High solubility and high dose challenges Release control from Difficult to achieve dosage form • Zero order release • Combination of release patterns like IR+SR, IR+

  12. Slide 12: Wrap Matrix System

    Wrap Matrix System The Technology • Novel oral controlled drug delivery system based on pre- defined, precise and selective surface exposure Key Advantages • Once-a-day dosing • Ability to handle products with larger daily dose • Suitable for drugs with very high solubility • No residual drug in dos

  13. Slide 13: Products with Wrap Matrix Technology

    Products with Wrap Matrix Technology An Antiepileptic with high water solubility and very large dose. • Phase II study in India ongoing • To be filed in US as 505(b)(2) in Q1 2011-12 An Antihypertensive drug with high dose, high solubility • Phase II study ongoing • To be filed in US as 505(b)(2) in

  14. Slide 14: NDDS – Injectable and Topical Products

    NDDS – Injectable and Topical Products

  15. Slide 15: The Challenge of Delivering Hydrophobic Anticancer Drugs

    The Challenge of Delivering Hydrophobic Anticancer Drugs The Problem Conventional solution Limitations • Use of toxic surfactants and • Additional toxicity of non aqueous solvents surfactant limits the Water insoluble For e.g. Cremophor® EL and maximum tolerated dose Ethanol for paclitaxel and • Hyp

  16. Slide 16: “G11 ANVAWOD

    “G11 ANVAWOD HOuvasay G3DNVAGY vWuvHd NAS

  17. Slide 17: Paclitaxel Injection Concentrate for Nanodispersion (PICN)

    Paclitaxel Injection Concentrate for Nanodispersion (PICN) Novel formulation of Paclitaxel using SPARC’s proprietary nano particle platform technology • Achieves 30% higher drug concentrations in tumor tissues compared to conventional paclitaxel PICN after • Unlike ABRAXANE®, quick and easy “one ste

  18. Slide 18: Safety established at high doses in Phase I clinical trial

    Safety established at high doses in Phase I clinical trial Study enrolled 36 patients with Lower dose limiting toxicities compare to ABRAXANE®* metastatic breast cancer and who have progressed to at least one combination PICN ABRAXANE®† TAXOL®† chemotherapy. 260mg/m2 260mg/m2 175mg/m2 n= 9 , (%) n=2

  19. Slide 19: Encouraging trend of efficacy in Phase I clinical study

    Encouraging trend of efficacy in Phase I clinical study Key Findings from Interim Efficacy Data Analysis Lower dose limiting toxicities compare to ABRAXANE®* • Efficacy of PICN is being evaluated for PICN ABRAXANE®† TAXOL®† 2 dose levels. 260mg/m2 260mg/m2 175mg/m2 • 260mg/m2 in 9 patients n= 9 , (%

  20. Slide 20: Future development plan

    Future development plan US –505(b)(2) route. • Pre-IND meeting with USFDA completed and obtained guidance from FDA for possible registration • To initiate Phase I study of a combination chemotherapy of PICN with Carboplatin Q3 2010-11 India • To initiate a phase II/III study in metastatic breast can

  21. Slide 21: “G11 ANVAWOD

    “G11 ANVAWOD HOuvasay G3DNVAGY vWuvHd NAS

  22. Slide 22: DICN Future development plan

    DICN Future development plan US –505(b)(2) route. • Pre-IND meeting with USFDA in FY 2010 – 11 India • Initiated a phase I study in solid tumor patients

  23. Slide 23: Challenges in Delivering Injectable Drugs for Chronic Use

    Challenges in Delivering Injectable Drugs for Chronic Use The Challenge Chronic treatment of certain There are long acting depot diseases require maintenance of injections in the market which solve systemic drug levels round the most of these problems. However, clock. limitations are • Products requ

  24. Slide 24: Biodegradable Depot Injections and Implants

    Biodegradable Depot Injections and Implants The Technology • SPARC has developed a technology platform of Peptide biocompatible and biodegradable micron-sized polymer Polymer particles that contains drug molecule in its matrix for long- Matrix term systemic delivery of drugs. Key Advantages • Simple

  25. Slide 25: Goserelin Depot Inj. 1 Month

    Goserelin Depot Inj. 1 Month Goserelin is a LHRH analogue used for the treatment of hormone dependant tumors such as prostate cancer, breast cancer & endometriosis. SPARC has developed Goserelin depot 1M Inj. using its proprietary biodegradable depot injection platform. • “Tailored release” to last

  26. Slide 26: Octreotide Depot Inj 1 M

    Octreotide Depot Inj 1 M • Octreotide depot Inj. (1 Month) is developed at SPARC with biodegradable depot injection platform. • Chemical and Bioequivalence of this product with the Sandostatin® LAR has been established in series of studies undertaken at SPARC • Octreotide depot Inj. is launched in I

  27. Slide 27: Future development plan

    Future development plan US • Goserelin Depot Inj 1 M IND filing in Q1 2011 -12 • Octreotide Depot Inj IND filing in Q1 2011-12 India • Goserelin Depot 1 M Clinical trial is initiated in April’10

  28. Slide 28: The Challenges of Delivering Inhaled Drugs

    The Challenges of Delivering Inhaled Drugs The Challenge Developing a Dry Powder Inhaler Developing a Dry Powder Inhaler which is compliant to the stringent device that overcomes US FDA and European requirements • Low drug delivery to lungs • Double dosing • Complex design and need for training of p

  29. Slide 29: Dry Powder Inhaler

    Dry Powder Inhaler The Technology • SPARC’s DPI is a pre-metered, 60 dose, inhalation activated device for administration of combination of inhaled steroids and bronchodilator drugs • Uniform dose delivery independent of inspiratory flow rate • Consistently delivers higher amount of drug to lungs •

  30. Slide 30: Equivalent clinical efficacy at half the dose of Seretide Accuhaler

    Equivalent clinical efficacy at half the dose of Seretide Accuhaler® Randomized, Comparative, Active Controlled, Multi-Center Study in Asthma Patients in India • Comparing • SPARC DPI containing Salmeterol 25mcg / Fluticasone 250mcg (TEST) & • Seretide Accuhaler® –(Salmeterol 50mcg / Fluticasone 500

  31. Slide 31: Equivalent efficacy at half the dose of Seretide Accuhaler

    Equivalent efficacy at “half the dose” of Seretide Accuhaler® Average Morning PEFR by Treatment Group FEV1 from baseline to week 4 (n = 107) by Treatment Week (n = 107) 3 420 2.5 2 1.99 Mean FEV1 L 1.94 Mean PEFR L/min 370 1.89 312.39 317.92 2 299.11 1.64 Test 320 282.9 1.88 1.87 Test 1.79 1.81 Refe

  32. Slide 32: Future development plan

    Future development plan US –505(b)(2) route. • Pre IND meeting in FY 2010-11 India • Phase III study completed • To be launched in Q3 2010-11

  33. Slide 33: Challenges in Ophthalmic Delivery of Lipophilic Drugs

    Challenges in Ophthalmic Delivery of Lipophilic Drugs Challenge • Development of ophthalmic dosage forms of water insoluble prostaglandin analogues without the use of toxic surfactants. • Stabilization of highly susceptible prostaglandins at ambient conditions Conventional solution • Use of a preser

  34. Slide 34: “G11 ANVAWOD

    “G11 ANVAWOD HOuvasay G3DNVAGY vWuvHd NAS

  35. Slide 35: Latanoprost “BAK Free” Ophthalmic Solution

    Latanoprost “BAK Free” Ophthalmic Solution Clear, colorless, BAK-free ophthalmic solution Non-infringing formulation to the market leader Xalatan® (Pfizer) with similar strength, dosing, administration and pack size. Reduced risk of ocular surface damage on chronic use Stable at Room Temp.; does not

  36. Slide 36: Equivalent Efficacy in Clinical Study in India

    Equivalent Efficacy in Clinical Study in India IOP (morning) SPARC completed a 4 week, randomized,, active controlled, multi- 33 32 31 30 Average Study Eye IOP (mm Hg) 29 center, phase III study in India to 28 27 26.11* 26 25 24 25.03* compare safety and efficacy of SPARC’s 23 22 21 20 18.96* 19 17.

  37. Slide 37: Future development plan

    Future development plan US –505(b)(2) route. • IND approved at USFDA • USFDA requires 2 Phase III studies for possible product registration • An active controlled, non-inferiority, clinical study in 518 patients • Open label extension safety study in 200 patients. • Target start date of the study: J

  38. Slide 38: Challenges in Developing Once a Day Ophthalmic Formulations

    Challenges in Developing Once a Day Ophthalmic Formulations • To enhance the duration of action of short acting ophthalmic drugs • Localization of drug action with minimal The Challenge systemic absorption • To make clear and non irritating formulation which does not cause • uncomfortable adhesion e

  39. Slide 39: “G11 ANVAWOD

    “G11 ANVAWOD HOuvasay G3DNVAGY vWuvHd NAS

  40. Slide 40: Timolol Maleate Once a Day Ophthalmic Formulation

    Timolol Maleate Once a Day Ophthalmic Formulation • Clear colorless solution • Bioadhesive yet non-sticky. • Lubricating-film forming and day time use possible • Equivalent efficacy of Timolol maleate 0.5% administered once a daily was established in a clinical trial in 100 patients comparing with T

  41. Slide 41: Future Development Plan

    Future Development Plan Phase III clinical study completed in India Product launch in India – Q2 2010 - 11

  42. Slide 42: NCEs

    SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

  43. Slide 43: NCE candidates

    NCE candidates SUN-597 SUN-09 SUN-1334H SUN-44

  44. Slide 44: Desired Attributes of a Novel Antihistamine

    Desired Attributes of a Novel Antihistamine Selective Non – sedating Quick onset and Long duration of action Cardiac safety Suitability for oral and topical route Anti-inflammatory potential

  45. Slide 45: SUN-1334H Translating Preclinical to Clinical Advantage

    SUN-1334H Translating Preclinical to Clinical Advantage Preclinical Studies • Highly selective histamine H1 receptor antagonist; insignificant affinity for other receptors • Highly efficacious in allergic models • High safety index • Does not cross blood brain barrier as demonstrated in radio-labell

  46. Slide 46: SUN-1334H Ophthalmic Solution

    SUN-1334H Ophthalmic Solution • Although oral antihistamines can Edema Scores* cause reduction in symptoms of Treatment 0.5 hr 24 hr conjunctivitis, the topical administration gives advantage of Saline 0 0 quicker onset and better efficacy Placebo 17.67 16.42 • In preclinical studies, SUN-1334H SUN-

  47. Slide 47: SUN 1334H Future Development Plan

    SUN 1334H Future Development Plan SUN 1334H Oral • Chronic toxicity studies are on going • Cardiac and renal safety studies and mass balance studies in human volunteers are planned SUN 1334H Ophthalmic • Completed Pre-IND meeting with USFDA • To begin Phase I clinical study in India – Q3 2010-11 • I

  48. Slide 48: Desired Attributes of a Soft-steroid

    Desired Attributes of a Soft-steroid High efficacy on the target organs Long duration of action Suitable for different topical therapeutic application Low systemic bioavailability Rapid inactivation on systemic absorption Low potential for • Skin thinning • Increase in intra ocular pressure High the

  49. Slide 49: SUN-597 Superior Preclinical Profile

    SUN-597 Superior Preclinical Profile In vitro • High binding affinity for human glucocorticoid receptor Ki = 1.09nM • Good selectivity over other relevant sex hormone & mineralocorticoid receptors In vivo • Good potency, efficacy, and duration of effect in animal models of asthma and allergic rhinit

  50. Slide 50: SUN-597 High Therapeutic Index in Asthma Model

    SUN-597 High Therapeutic Index in Asthma Model Sephadex Lung Edema-ED50 (Rat) Liver Glycogen Deposition (Rat) (mg/kg, intratracheal) Dose: 3 mg/kg, 3 days, intratracheal Thymus Glycogen deposition Treatment Lung Edema Treatment Inhibition (mg/100 gm liver wt.) SUN-597 0.094 > 3* SUN-597 11.0 Cicleso

  51. Slide 51: SUN-597 Low Side Effect Potential

    SUN-597 Low Side Effect Potential Safety on Oral Administration in Rats Dose: 1 mg/kg x 7 days % Inhibition of % Inhibition of % Inhibition of Treatment Thymus Adrenal Body Weight Gain SUN-597 0 7.7 0 Ciclesonide 29.5 28.7 2.7 Fluticasone 50.3 21.2 49.2 propionate • No effect in 30-day intranasal to

  52. Slide 52: SUN-597 Nasal Efficacy in Allergic Rhinitis Model

    SUN-597 Nasal Efficacy in Allergic Rhinitis Model Nasal Formulation: 0.05% Suspension 40 35 SUN-597 as nasal formulation 30 Total dye (µg) shows good potency and efficacy 25 in preclinical in vivo models for allergic rhinitis 20 15 10 5 0 Non Sensitized Fluticasone S-597 Sensitized Control 40 µl 40µ

  53. Slide 53: Future development plan

    Future development plan SUN -597 Nasal • Phase I clinical trials to commence in Q2 - 2010-11 SUN-597 Inhalation • Dosage form development - FY 2010-11 • Sub-acute toxicity studies - FY 2010 -11

  54. Slide 54: Desired Attributes of Pro-drugs of Drugs with Limited Absorption

    Desired Attributes of Pro-drugs of Drugs with Limited Absorption Avoid transporter absorption window Facilitated absorption throughout the GI tract Conversion of pro-drugs to active drug upon absorption Enhanced drug bioavailability Low toxic potential of pro-moiety Faster onset of action Dose depen

  55. Slide 55: “G11 ANVAWOD

    “G11 ANVAWOD HOuvasay G3DNVAGY vWuvHd NAS

  56. Slide 56: SUN-09 Achieves Better Bioavailability of Baclofen

    SUN-09 Achieves Better Bioavailability of Baclofen Dose: 20 mg/kg, intracolonic in rat AUC0-t Treatment Tmax (hr) (µg.hr/ml) • In animal studies, intra-colonic administration of SUN-09 results in Baclofen 1.17 2.4 higher levels of baclofen compared to similar administration of baclofen Baclofen on S

  57. Slide 57: SUN-09 Significantly Superior Efficacy than Baclofen

    SUN-09 Significantly Superior Efficacy than Baclofen Percentage Reduction of Rotarod Performance in Mice Dose Treatment % Reduction (mg/kg, p.o.) • Oral administration of SUN-09 gives SUN-09 20.8 53.6 dose-dependent muscle relaxation with rapid onset of action in mice 31.2 81.2 • SUN-09 does not sho

  58. Slide 58: SUN-09 Future Development Plan

    SUN-09 Future Development Plan India • IND approved by DCGI • Phase I clinical study to commence in Q3 2010-11

  59. Slide 59: SUN-44 Promising Preclinical Profile

    SUN-44 Promising Preclinical Profile • SUN-44 is a pro-drug of gabapentin intended to increase bioavailability (drug exposure), hasten onset of Dose effect and reduce inter-individual AUC0-t Tmax Treatment (mg/kg, (µg.hr/ml) (hr) variability p.o.) Gabapentin 100 88.14 2 • Limitations in the pharmaco

  60. Slide 60: SUN-44 Superior to Gabapentin

    SUN-44 Superior to Gabapentin % % Dose Incidence Protection Treatment (mg/kg, p.o.) of Tonic from • In animal model of epilepsy, SUN-44 (Mice) Extensor Mortality shows better efficacy compared to gabapentin 35 37.5 40 • SUN-44 reduces the latency and SUN-44 70 0.0 100 incidence of tonic extensor and

  61. Slide 61: SUN-44 Current Status

    SUN-44 Current Status Preclinical safety studies do not indicate additional liabilities in terms of safety SUN-44 as a pro-drug does not release reactive acetaldehyde moiety, hence no alteration of protein or enzymes are expected. Neither there is possibility of acetaldehyde related organ toxicities

  62. Slide 62: SUN–44 Future Development Plan

    SUN–44 Future Development Plan IND filed in INDIA Phase I to commence in FY 2010 - 11

  63. Slide 63: For updates and specific queries, please visit www.sunpharma.in

    For updates and specific queries, please visit www.sunpharma.in or feel free to contact Uday Baldota Mira Desai Tel : +91 22 6645 5645, Ext 605 Tel : +91 22 6645 5645, Ext 606 Tel Direct : +91 22 66455605 Tel Direct : +91 22 66455606 Mobile : +91 98670 10529 Mobile : +91 98219 23797 uday.baldota@sun

Sun Pharma Advanced Research Company — Investor Presentation (June 2010) on 6ix